Alzheimer’s drug gets FDA panel’s backing, setting the stage for broader use

Health advisers on Friday unanimously backed the full approval of a closely watched Alzheimer’s drug, a key step toward opening insurance coverage to U.S. seniors with early stages of the brain-robbing disease.